Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the effectiveness of adding RCP (redensyl, capixyl, procapil) to a hair loss treatment regimen that includes minoxidil and finasteride. Users share experiences, suggesting RCP may not be as effective as minoxidil, but could be useful for creating topical solutions.

Mixing RU58841 with minoxidil compounded with tretinoin is discussed, with concerns about systemic absorption. Topical dutasteride and finasteride are also mentioned as treatments, with varying personal experiences and concerns about side effects.

Creating a topical solution combining finasteride and stemoxydine to treat hair loss, and the discussion of whether 15mg of finasteride would be sufficient for 60ml solvent.

The conversation is about concerns over using a combination spray containing finasteride, minoxidil, and ketoconazole for hair loss. The user is worried about potential scalp irritation and considers using separate products to better manage sensitivity.

3aHSD enzyme's role in hair loss and a crowdfund for research. Goal: explore new treatments, study RU58841, and develop natural topical product.

A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.

The post discusses the high cost of a topical hair loss treatment from Happy Head, which contains finasteride, minoxidil, retinoic acid, and hydrocortisone. The user is seeking cheaper alternatives, specifically asking if there are compounding pharmacies that can recreate the same or similar formulation.

The user is considering making a homemade topical finasteride solution using an ethanol-based carrier. They are inquiring if a solution containing partially denatured ethyl alcohol and benzalkonium chloride is suitable.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

The user mixed Pyrilutamide with a KB solution and noticed some undissolved powder, questioning if more shaking or liquid is needed. They use Pyrilutamide from Anagenic.

The safety of combining alfatradiol and fluridil with finasteride as a potential treatment for male pattern baldness, which is approved in the European Union. Other treatments such as minoxidil and RU58841 were also discussed.

Formula 82M, a minoxidil and retinol liquid, improved hair texture and filled in temples with baby hairs for the user, but its high cost and lack of reviews cause concern. Another user mentioned using a similar product, 82F, which has become less effective and expensive over time.

The conversation discusses the difficulty of applying tretinoin 0.025% cream on the scalp and considers switching to a gel for easier application. It also mentions that a liquid solution, ideally combined with minoxidil, may be more effective for hair treatment.

The user is considering adding a topical treatment to their current regimen of finasteride and oral minoxidil to protect their temple area, with options like piro, RU58841, or topical finasteride or dutasteride. They are advised against overcomplicating their treatment, but another user suggests a topical with 8% minoxidil/dutasteride for better results.

Oleic acid and microneedling are being explored for hair regrowth, but results are mixed. Addressing DHT and fibrosis is crucial, with treatments like finasteride, minoxidil, and scalp massage also discussed.

The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactin receptor inhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.

The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.

The conversation discusses the effectiveness and cost of using Hair + Me for Minoxidil, with some users suggesting buying treatments separately or from online pharmacies for savings. A user mentions a positive experience with Hair + Me for Minoxidil and Skin+Me for skincare.

The user is seeking a topical minoxidil and finasteride combination without propylene glycol due to scalp irritation. They are looking for a supplier in the US.

The user is using a topical solution containing 1% finasteride and 5% minoxidil for hair loss, with water, glycerin, and PEG-40 hydrogenated castor oil as carrier agents. They are questioning if these ingredients are effective carriers after using the solution for three months.

Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.

A user wants to add tretinoin to their nightly minoxidil and finasteride combo to increase effectiveness. They seek advice on how to mix tretinoin with the existing treatment.

Veradermics has a market cap over a billion dollars, comparable to Cosmo pharmaceutical. Users discuss using Kintor's Pirylutamide for hair loss.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

Mixing Dutasteride with MCT oil may improve absorption due to its fat-soluble nature. Users suggest taking it with whole milk or using oil-based capsules for better effectiveness.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

A topical treatment called 1961, containing multiple products, is discussed for its compatibility with finasteride. It is suggested that 1961 does not negatively affect finasteride's effectiveness and may even enhance its absorption.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

The user is considering PRP with exosomes for hair loss after oral minoxidil and dutasteride failed to provide desired results. Despite suggestions for a hair transplant, the user is hesitant due to cost and complexity, and is unsure about other options.